Search Results for "Diabetes"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Diabetes. Results 251 to 260 of 385 total matches.
Midodrine for Orthostatic Hypotension
The Medical Letter on Drugs and Therapeutics • Jun 20, 1997 (Issue 1003)
syndromes including Parkinson’s disease, diabetic neuropathy, pure autonomic failure and
Shy-Drager ...
Midodrine hydrochloride (ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition include other sympathomimetics, constrictive garments, erythropoietin (Epogen; Procrit) and fludrocortisone with salt (D Robertson and TL Davis, Neurology, 45 suppl 5: S26, 1995).
Cool.click: A Needle-free Device For Growth Hormone Delivery
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001 (Issue 1095)
diabetes mellitus, most reported that injecting saline
with cool.click was less painful than ...
A new needle-free system (cool.click) has been approved by the FDA for subcutaneous delivery of Saizen (recombinant somatotropin - Serono). Somatotropin is used for long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. Children with growth hormone deficiency require injections daily or several times weekly for many years.
Lurasidone (Latuda) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011 (Issue 1358)
.
Extrapyramidal Elevated QTc Weight
Drug Diabetes Symptoms Prolactin Prolongation Gain
Aripiprazole ...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic,
for oral treatment of schizophrenia in adults.
Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jul 08, 2013 (Issue 1420)
artery
disease, heart failure, cerebrovascular disease, diabetes
with end-organ damage or migraine ...
The FDA has approved Quartette (Teva), an extended-cycle
combination oral contraceptive containing increasing
doses of the estrogen ethinyl estradiol (EE)
combined with the progestin levonorgestrel (LNG). The
rationale is that a gradual increase in the EE dose may
reduce unscheduled bleeding or spotting, a common
adverse effect of extended-cycle oral contraceptives.
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
diabetes, worsening hypoglycemia,
The Medical Letter ® Vol. 65 (1674) April 17, 2023
63
metabolic ...
Since our initial review of the oral lipid-lowering
adenosine triphosphate-citrate lyase (ACL) inhibitor
bempedoic acid (Nexletol – Esperion) in 2020,
cardiovascular outcomes data in statin-intolerant
patients have become available.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):62-3 doi:10.58347/tml.2023.1674b | Show Introduction Hide Introduction
Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
such as diabetic foot
and decubitus ulcer infections, human and animal
bites, and necrotizing fasciitis ...
The FDA has approved delafloxacin (Baxdela –
Melinta), an anionic fluoroquinolone antibiotic, for oral
and parenteral treatment of adults with acute bacterial
skin and skin structure infections (ABSSSIs), including
those caused by methicillin-resistant Staphylococcus
aureus (MRSA). It is the first fluoroquinolone to be
approved for treatment of MRSA.
Tacrolimus FK506 Organ Transplants
The Medical Letter on Drugs and Therapeutics • Sep 16, 1994 (Issue 931)
), gastrointestinal disturbances (diarrhea,
nausea, vomiting), hyperkalemia, hyperglycemia and new onset of diabetes ...
Tacrolimus (Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving liver transplants. The drug has also been used as rescue therapy for organ graft rejection unresponsive to cyclosporine (Sandimmune) and other immunosuppressive drugs.
Sildenafil: An Oral Drug for Impotence
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
significant improvement in subgroups with cardiovascular disease, diabetes, transurethral prostatectomy ...
Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).
Update on Glucosamine For Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001 (Issue 1120)
), but exacerbation or development of diabetes has
not been reported in clinical trials of oral glucosamine taken ...
Since the last Medical Letter article on glucosamine for osteoarthritis (vol.39, page 91, September 26, 1997), more data have become available. Glucosamine is available in US pharmacies and health food stores as sulfate, hydrochloride or n-acetyl salt.
Drug-eluting Stents
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
. The risk of in-stent restenosis is increased in patients with diabetes, small vessels, long coronary ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.